Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.

Keywords:
Contrast-induced nephropathy, Metoprolol, Carvedilol, Cystatin C, Malondialdehyde
1.
Heyman SN, Reichman J, Brezis M: Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:685-691.
2.
Berkseth RO, Kjellstrand CM: Radiologic contrast-induced nephropathy. Med Clin North Am 1984;68:351-370.
3.
Messana JM, Cieslinski DA, Nguyen VD, Humes HD: Comparison of the toxicity of the radiocontrast agents, iopamidol and diatrizoate, to rabbit renal proximal tubule cells in vitro. J Pharmacol Exp Ther 1988;244:1139-1144.
4.
Yoshioka T, Fogo A, Beckman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992;41:1008-1015.
5.
Cox CD, Tsikouris JP: Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol 2004;44:327-337.
6.
Freuerstein GZ, Sponer G: The adrenergic pharmacology of carvedilol. Heart Fail Rev 1999;4:21-27.
7.
Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN: Increased oxidative stress in patients with heart failure. J Am Coll Cardiol 1998;31:1352-1356.
8.
Flesch M, Maack C, Cremers B, Baumer AT, Südkamp M, Böhm M: Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999;100:346-353.
9.
Satoh K: Serum lipid peroxide in cerebrovascular disorders determined by new colorimetric method. Clin Chim Acta 1978;90:37-43.
10.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
11.
Woo KS, Choi JL, Kim BR, Kim JE, Han JY: Clinical usefulness of serum cystatin C as a marker of renal function. Diabetes Metab J 2014;38:278-284.
12.
Harmoinen A, Lehtimaki T, Korpela M, Turjanmaa V, Saha H: Diagnostic accuracies of plasma creatinine, cystatin C and glomerular filtration calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem 2003;49:1223-1225.
13.
Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, Riesen W, Wuthrich RP: Time course of cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004;61:98-102.
14.
Ebru AE, Kilic A, Korkmaz FS, Seker R, Sasmaz H, Demirtas S, Biyikli Z: Is cystatin-C superior to creatinine in the early diagnosis of contrast-induced nephropathy? A potential new biomarker for an old complication. J Postgrad Med 2014;60:135-140.
15.
Ishibashi Y, Yamauchi M, Musha H, Mikami T, Kawasaki K, Miyake F: Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology 2010;61:724-730.
16.
Wacker-Gussmann A, Bühren K, Schultheiss C, Braun SL, Page S, Saugel B, Schmid S, Mair S, Schoemig A, Schmid RM, Huber W: Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: a prospective study in 374 patients. AJR Am J Roentgenol 2014;202:452-458.
17.
Cicek M, Yıldırır A, Okyay K, Yazici AC, Aydinalp A, Kanyilmaz S, Muderrisoglu H: Use of α-lipoic acid in prevention of contrast-induced nephropathy in diabetic patients. Ren Fail 2013;35:748-753.
18.
Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, Anselmi M, Ferrero V, Yabarek T, Sorio A, Rizzotti P, Lupo A, Vassanelli C: Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012;58:458-464.
19.
Halliwel B: Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994;344:721-724.
20.
Gutteridge JM, Halliwel B: Free radicals and antioxidants in the year 2000. A historical look to the future. Ann NY Acad Sci 2000;899:136-147.
21.
Chang JM, Kuo MC, Kuo HT, Chıu YW, Chen HC: Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med 2005;146:210-215.
22.
Devrim E, Cetin M, Namuslu M, Erguder IB, Cetin R, Durak I: Oxidant stress due to nonionic low osmolar contrast medium in rat kidney. Indian J Med Res 2009;130:433-436.
23.
Colbay M, Yuksel S, Uslan I, Acarturk G, Karaman O, Bas O, Mollaoglu H, Yagmurca M, Ozen OA: Novel approach for the prevention of contrast nephropathy. Exp Toxicol Pathol 2010;62:81-89.
24.
Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, et al; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, et al: 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
25.
Fares H, Lavie CJ, Ventura HO: Vasodilating versus first-generation β-blockers for cardiovascular protection. Postgrad Med 2012;124:7-15.
26.
Módolo NS, Castiglia YM, Ganem EM, Braz JR, Vianna PT, Vane LA: Acute renal ischemia model in dogs: effects of metoprolol. Ren Fail 2001;23:1-10.
27.
Jenkins RR, Del Signore CM, Sauer P, Skelly C: The effect of β blocking drugs on lipid peroxidation in rat heart in vitro. Lipids 1992;27:539-542.
28.
Maffei A, Lembo G: Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis 2009;3:317-327.
29.
Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Münzel T: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006;48:677-684.
30.
Avcı E, Yeşil M, Bayata S, Postacı N, Arıkan E, Cirit M: The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyol Derg 2011;11:613-617.
31.
Günebakmaz Ö, Kaya MG, Koç F, Akpek M, Kasapkara A, İnanç MT, Yarlioglues M, Calapkorur B, Karadag Z, Oguzhan A: Does nebivolol prevent contrast-induced nephropathy in humans. Clin Cardiol 2012;35:250-254.
32.
Akgüllü C, Eryılmaz U, Güngör H, Huyut A, Zencir C, Hekim T: A clinical study about contrast nephropathy: risk factors and the role of β blockers. Anatol J Cardiol 2015;15:232-240.
33.
Akgüllü Ç, Hekim T, Eryılmaz U, Boyacıoğlu M, Güngör H, Meteoğlu İ, Karul A: The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats. Ren Fail 2015;22:1-7.
34.
Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC: Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact 2011;189:45-51.
35.
Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G: High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol 2011;57:771-778.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.